Moshe Barel, cofounder and CEO of medtech company AccuLine, thinks a four-minute AI assessment can change all that. The ...

OpenAI has revealed a breakthrough proof that overturns a nearly 80-year-old geometry conjecture posed by Paul Erdős.

Genes contain instructions for making proteins, and a central dogma of biology is that this information flows from DNA to RNA to proteins. But only two percent of the human genome actually encodes ...

It’s hard to deny the momentum of prediction markets. Platforms like Polymarket and Kalshi gained widespread attention in 2024 for letting people wager money on the U.S. presidential election, but ...

Putin’s Trip to China Future of Warfare Russian Forces Struggle ‘The Death Zone’ Photos Advertisement Supported by Nonfiction In “Project Maven,” Katrina Manson shows us how close we are to artificial ...

Current Climate brings you the latest news about the business of sustainability every Monday. Sign up to get it in your inbox. An exploratory well at Zanskar's Big Blind site in Nevada. Interest in ...

When he's not testing the latest phones or phone cameras, Andrew can normally be found with his own camera in hand or behind his drums or eating his stash of home-cooked food -- sometimes all at once.

AI developer Anthropic says its newest Claude artificial intelligence model is so good at finding cybersecurity vulnerabilities that it's not releasable to the public. The company is instead providing ...

The featured gameplay demonstrates a specialized modification in Minecraft that automates the mining process for various resources. When a player strikes a single block within an ore vein, the mod ...

To find the mallet at Howling Hills, go to the table directly beside the huge gate that a number of NPCs are working on, and you can find the mallet there, beside some other tools. If you watch the ...

Finerenone significantly improves eGFR slope in patients with nondiabetic chronic kidney disease, suggesting a slowed progression of renal decline. Topline results were announced from a phase 3 trial ...